FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely oncology and clinical biochemistry, and aims at early diagnosis of renal cell carcinoma. A method for diagnosing renal cell carcinoma involves determining the presence in the blood serum of antibodies to visual arrestin – arrestin 1. Antibodies to arrestin 1 are used as a biomarker for diagnosing renal cell carcinoma.
EFFECT: using the group of inventions provides effective and minimally invasive early diagnosis of renal cell carcinoma, which significantly increases the probability of a positive outcome for the patient when observing the given pathology.
3 cl, 1 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR EARLY DIAGNOSIS OF RENAL CELL CARCINOMA BY OBSERVING PRESENCE OF VISUAL ARRESTIN IN BLOOD SERUM | 2020 |
|
RU2741245C1 |
| METHOD OF DIAGNOSING RENAL CELL CARCINOMA BY PRESENCE OF ARRESTIN AND RECOVERIN VISUAL PROTEINS IN URINE | 2022 |
|
RU2805811C1 |
| METHOD FOR SPECIFYING LABORATORY DIAGNOSIS OF RENAL CELL CARCINOMA | 2021 |
|
RU2766295C2 |
| METHOD OF DIAGNOSTICS OF KIDNEY DAMAGE IN CHILDREN WITH VESICOURETERAL REFLUX | 2023 |
|
RU2814399C1 |
| METHOD FOR SCREENING PROBABILITY OF BLADDER CANCER | 2019 |
|
RU2718284C1 |
| SYSTEM AND METHOD FOR SCREENING THE PROBABILITY OF HAVING COLORECTAL CANCER | 2018 |
|
RU2698854C1 |
| METHOD FOR SCREENING PROBABILITY OF BREAST CANCER PRESENCE | 2019 |
|
RU2718272C1 |
| APPLICATION OF PEPTIDE COMPOUND FOR APOPTOSIS INDUCTION IN A TUMOR CELL | 2022 |
|
RU2796104C1 |
| METHOD FOR EARLY DIAGNOSIS OF LUNG CANCER | 2018 |
|
RU2697971C1 |
| METHOD FOR SCREENING PROBABILITY OF KIDNEY CANCER | 2023 |
|
RU2816798C1 |
